Skip to main content

Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January 29, 2021)

Additional link
Description
Describes the approaches taken at the federal, state, and local/institutional levels to ensure an effective, equitable, and fair allocation of COVID-19 monoclonal antibody (mAbs) therapies. Highlights challenges in reaching underserved patients, and discusses access and equity considerations for mAbs treatment.
Date
01/2021
Type
Document
Organization
National Academies of Sciences, Engineering, and Medicine
Tagged as
Access · Health disparities · Specialty care